解读人类肠道微生物群和口服抗糖尿病药物之间的独特和共同的相互作用
Huahui Ren1,2, Zhun Shi1, Fangming Yang1
1BGI Research Shenzhen China.
iMeta
|June 17, 2024
概括
口服抗糖尿病药物 (OADs) 改变了2型糖尿病患者的肠道微生物群. 甲基和柏柏林比其他OADs显示出更大的肠道微生物变化,基线微生物群预测治疗反应.
科学领域:
- 微生物学 微生物学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病是一种代谢障碍.
- 肠道微生物群在代谢健康中起着重要作用.
- 口服抗糖尿病药物 (OADs) 通常用于管理2型糖尿病.
研究的目的:
- 调查不同OAD对肠道微生物群组成的影响.
- 为了比较阿卡尔,柏柏林,甲福林,维尔达格利普丁和格利皮齐德对肠道微生物群的影响.
- 探索基线肠道微生物群与OAD治疗反应之间的关联.
主要方法:
- 分析2型糖尿病患者的肠道微生物群组成.
- 使用各种OADs,包括阿卡尔,贝贝林,甲福林,维尔达格利普丁和格利皮齐德.
- 统计分析以将微生物群变化与药物治疗和患者反应相关联.
主要成果:
- 在2型糖尿病患者的肠道微生物群中,OADs会引起明显和共同的改变.
- 与甲福明,维尔达格利普丁和格利皮齐德相比,阿卡尔和柏柏林对肠道微生物群的影响更为显著.
- 基线肠道微生物组成与对OADs的治疗反应密切相关.
结论:
- 不同的OAD对肠道微生物群产生不同的影响.
- 肠道微生物群调节是某些OAD的一个关键机制.
- 基于基线肠道微生物群的个性化OAD治疗可能会改善2型糖尿病的治疗结果.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
170
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
170
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Sulfonylureas
200
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
200
Factors Influencing Drug Absorption: Disease States and Pharmacology
492
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
492


